Innovation and Expertise
in Life Sciences Investing
Alta Partners is a leading venture capital firm in life sciences, funding over 145 companies in the industry since 1996. Our diverse and integrated team brings together a powerful depth of knowledge and experience, delivering tangible results for our companies and our investors.
- May 15, 2012
Achaogen Announces All Objectives Met in Phase 2 Plazomicin Complicated Urinary Tract Infections Study and Start of First-in-Human Study with ACHN-975
- May 08, 2012
Sutro Closes $16.5 Million Second Tranche of Series C Financing
- May 03, 2012
Sunesis Pharmaceuticals Receives European Orphan Drug Designation for Vosaroxin to Treat Acute Myeloid Leukemia
- May 03, 2012
Silence Therapeutics’ Partner, Quark Pharmaceuticals, Extends its Agreement with Pfizer to Develop One of its Compounds Containing Silence’s AtuRNAi in a New Indication
- May 03, 2012
Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation for South Korean Market
- May 02, 2012
Trevena Enters Research Collaboration with Merck To Identify Novel Biased Ligand Molecules
- Achaogen, Inc.
- Avid Radiopharmaceuticals, Inc.
- Esperion Therapeutics (spin-out)
- Excaliard Pharmaceuticals
- Immune Design Corp.
- MAKO Surgical
- Pathwork Diagnostics
- Sutro Biopharma
- See our complete portfolio ...
